Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and tremelimumab with personalized, standard-dose, or on-demand SIRT in unresectable hepatocellular carcinoma
2020-003925-42Phase 2Active
- Sponsor
- LMU Klinikum
- Start
- May 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC) (3 arms), sponsored by LMU Klinikum. Primary endpoint: Objective Response Rate. Started May 2021; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2020-003925-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003925-42.